Leukemia: Clinical Trials

13 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 enrolling by invitation. 13 Phase 2, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Enrolling by invitation 13
Phase 34Enrolling by invitation 4

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital732026-09-012026-09-10
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Enrolling by invitationBnai Zion Medical Center122026-06-012026-07-08
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
Phase 2Enrolling by invitationSWOG Cancer Research Network552026-04-132026-10-05
VEN+IDAC vs IDAC in AML
Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia)
Phase 2 / Phase 3Enrolling by invitationGuangdong Second Provincial General Hospital2322026-04-012026-04-17
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital402026-04-012026-04-08
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University2672026-03-012026-06-16
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University4502026-03-012026-06-16
RVU120 Rollover Study
RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
Phase 2Enrolling by invitationRyvu Therapeutics SA142025-12-042026-09-17
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia
Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases
Phase 2Enrolling by invitationNational Institute of Pediatrics, Mexico1202025-02-012025-03-14
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
venetoclax - Acute Promyelocytic Leukemia
Phase 2 / Phase 3Enrolling by invitationThe First Affiliated Hospital of Soochow University982023-08-012024-08-09
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia
Phase 2Enrolling by invitationMichael Pulsipher302021-08-242025-05-04
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
ASTX727 - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Enrolling by invitationTaiho Oncology, Inc.3322019-09-302026-07-28
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
CliniMacs TCR alpha-beta-Biotin system - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2Enrolling by invitationMichael Pulsipher502015-10-012025-05-04

Narrower conditions

Leukemia, Myeloid, Acute (8)  ·  Myelodysplastic Syndromes (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Neoplasm, Residual (2)  ·  Gastrointestinal Diseases (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Hairy Cell (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Leukemia, Promyelocytic, Acute (1)  ·  Neoplasm Metastasis (1)  ·  Recurrence (1)

Broader conditions

Hematologic Diseases (13)  ·  Hemic and Lymphatic Diseases (13)  ·  Neoplasms (13)  ·  Neoplasms by Histologic Type (13)  ·  Leukemia, Myeloid (9)  ·  Immune System Diseases (5)  ·  Immunoproliferative Disorders (5)  ·  Lymphatic Diseases (5)  ·  Lymphoproliferative Disorders (5)  ·  Leukemia, Lymphoid (4)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Bone Marrow Diseases (3)  ·  Neoplastic Processes (3)

Interventions

Azacitidine (2)  ·  Induction Chemotherapy (2)  ·  Opiate Substitution Treatment (2)  ·  Cytarabine (1)  ·  Homoharringtonine (1)  ·  Lisaftoclax (1)  ·  Maintenance (1)  ·  decitabine and cedazuridine drug combination (1)  ·  ruxolitinib (1)  ·  venetoclax (1)  ·  zanubrutinib (1)

Sponsors

Guangdong Second Provincial General Hospital (3)  ·  First Affiliated Hospital of Zhejiang University (2)  ·  Michael Pulsipher (2)  ·  Bnai Zion Medical Center (1)  ·  National Institute of Pediatrics, Mexico (1)  ·  Ryvu Therapeutics SA (1)  ·  SWOG Cancer Research Network (1)  ·  Taiho Oncology, Inc. (1)  ·  The First Affiliated Hospital of Soochow University (1)

Countries

China (6)  ·  United States (4)  ·  France (2)  ·  Poland (2)  ·  Armenia (1)  ·  Austria (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)  ·  Romania (1)  ·  Slovakia (1)

Top investigators

Anjali S Advani (1)  ·  Guopan Yu, PhD (1)  ·  Michael L Pulsipher, MD (1)  ·  Michael Pulsipher, MD (1)  ·  Sara Espinosa-Padilla, Ph.D. (1)

Results publications

PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 35776909, PMID 39042892, PMID 9718381

NIH funding

2018 (1), 2025 (1)